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a b s t r a c t
Four 24/7 P-PCI centres performed emergency programme in 2011 in Slovakia. In view of the
geographic relations and number of residents per centre (1.37 million residents/centre) it
was possible to consider access to P-PCI as sub-optimal. The aim of the study is an evaluation
of two-year survival of STEMI cohort admitted to hospitals in 2011 and confrontation of
survival with used treatment strategy. Clinical outputs were analysed using data acquired
from the SLOVak registry of Acute Coronary Syndromes (SLOVAKS). In this analysis we have
evaluated 1580 cases of ACS (STEMI, UAP and NSTEMI).
80.6% of STEMI patients have been admitted into P-PCI centres via primary or secondary
transfer. Primary reperfusion treatment was accomplished in 76.0% of patients (64.7%
primary PCI, 11.3% ﬁbrinolysis). 82.3% STEMI patients were admitted within 12 h of symp-
toms onset. The median of total ischaemic time was 219 min. In the analysed cohort of
STEMI patients an in-hospital mortality of 5.99%, a 30-day mortality of 10.7%, a one-year
mortality of 14.6% and a two-year mortality of 17.6% was recorded. The two-year survival of
patients treated with P-PCI was signiﬁcantly better compared with patients without primary
reperfusion treatment (HR 0.4, p < 0.001) and comparable with patients treated by throm-
bolysis ( p = 0.66). A total of 90.7% of patients after thrombolysis, however, subsequently
underwent coronary angiography and as needed a rescue or delayed PCI was performed.
Pharmacoinvasive strategy represented the sub-group with the best prognosis, even though
the beneﬁt versus the sub-group treated with primary PCI did not achieve statistical
signiﬁcance (p = 0.164). In patients with P-PCI who died, the median of the total ischaemic
time (the symptoms-PCI interval) was 300.5 min, while in patients who survived to two years
the median was 230.5 min ( p = 0.043). Signiﬁcantly worse two-year survival was observed in
diabetics (HR 1.63, 95% CI, p = 0.03).
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Statistical analysis
Conclusions: In 2011 it was possible to record a continuation of the favourable trend in the
management of patients with STEMI in Slovakia. The greatest challenge for health care
workers in the coming years will be to ensure primary reperfusion treatment for patients in
the desired time intervals. Our analysis conﬁrms the excellent prognosis of patients
managed through a pharmacoinvasive strategy. The mid-term survival of patients after
ACS in Slovakia points to worse results in comparison with results from abroad, which could
be associated with an unfavourable length of total ischaemic time and less consistent
secondary prevention could be speculated.
# 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp. z o.o.
All rights reserved.
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.Table 1 – The number of ACS cases reported in 2011 and
type of ACS distribution.
n (2 months data) %
ACS 1580 100
STEMI 484 30.6
NSTEMI 565 35.8
UA 518 32.8
ACS with LBBB 13 0.8Introduction
International clinical experience has conﬁrmed that the
implementation of evidence-based medicine into daily prac-
tice can on the one hand impact the incidence and prevalence
of STEMI in a principal way and on the other hand affect the
prognosis of these patients. Implementation of the ofﬁcial
ESC-STEMI guidelines into clinical practice, however, is not
necessarily easy and differs signiﬁcantly in individual coun-
tries to the extent that it involves time delays as well as in-
depth implementation. Among the possibilities for speeding
up implementation are the use of targeted activities and
organisational measures. Four workplaces in Slovakia
(Bratislava, Nitra, Banská Bystrica and Košice) performed
24-h emergency medical services for primary percutaneous
intervention (P-PCI) in 2011, and the theoretical net time for
transport from a district hospital to PCI centres ranges from
15 to 120 min. In view of the geographic relations and number
of residents per centre (1.37 mil. residents/centre) it was
possible in 2011 to designate access to P-PCI as sub-optimal.
The aim of the study is to evaluate two-year survival of STEMI
cohort admitted to hospitals in 2011 and to compare survival
with used treatment strategy.
Patients and methods
Changes in clinical practice and clinical outputs were analysed
using data acquired from the SLOVak registry of Acute
Coronary Syndromes (SLOVAKS). SLOVAKS registry was based
in 2007 under the patronage of the Slovak Society of Cardiology
and National Institute of Health Informations and Statistics.
The data from 2007 to 2008 comes from continuous all year
character of data collection [1]. Since 2011 Slovak Society of
Cardiology has been organising SLOVAKS-2 registry based on
periodical two months snapshot data collection. The sub-
stantial change in methods of data acquisition in 2011
brought better hospital compliance, improved discipline of
reporting and more reliable data collection [2]. Survival
analysis relates to STEMI patients admitted to hospitals in
August and September 2011. Date of death and two-year
survival information in individual patient was picked up from
central web portal enabling veriﬁcation of current health
insurance status.Statistical analysis was performed using the SPSS programme.
Descriptive statistics was used for description of the sample.
x2-Tests were used to explore associations between nominal
variables and Mann–Whitney U-tests for analysis of association
between mortality and continual variables. Kaplan–Meier plots
were created and log-rank tests calculated to analyse the
association of mortality and demographic and medical vari-
ables.
Results
We have evaluated data from 69 treatment sites in Slovakia.
These sites represent 85% of all workplaces treating ACS
patients in the country, representing all cardiac centres and
local hospitals as well. In this analysis we have evaluated 1580
cases of ACS (STEMI, UAP and NSTEMI). STEMI cases represent
30.6% of all ACS (Table 1). The average age of patients with STEMI
was 63.8 (12.8). Representation of women was 30% ( Table 2).
Comorbidity and risk factors are presented in Table 3.
80.6% of STEMI patients have been admitted into PCI-
centres. It was done as the primary hospitalisation or
secondary transfer. The proportion of STEMI admitted via
EMS reached 88.7%. Primary reperfusion treatment was
accomplished in 76.0% of patients (64.7% primary PCI, 11.3%
ﬁbrinolysis). 82.3% STEMI patients were admitted within 12 h
of symptoms onset (Fig. 1). The median of total ischaemic time
in 2011 was 219 min (Fig. 2). There was a signiﬁcant increase of
total number STEMI patients treated with primary reperfusion
therapy ( p < 0.001) and primary PCI (p < 0.001) as well within
years 2007 to 2011 (Fig. 3). We have documented signiﬁcant
hospital mortality decrease since 1998, when the ﬁrst relevant
STEMI analysis in Slovakia has been done (Fig. 4).
Table 3 – Comorbidity and risk factors analysis.
All Male Female p
Diabetes 21.90% 18.20% 30.30% 0.003
Arter. hypertension 68.00% 63.40% 78.60% 0.001
Hyperlipoproteinemia 44.80% 44.20% 46.20% 0.691
Smoking 37.60% 44.50% 21.40% <0.001
Previous PCI 7.00% 7.70% 5.50% 0.396
Previous CABG 0.60% 0.90% 0.00% 0.256
Previous stroke 8.30% 7.70% 9.60% 0.001
Renal insufﬁciency 7.60% 5.30% 13.10% 0.003
Obesity 25.40% 21.20% 35.20% 0.001
Table 2 – Age and sex distribution in STEMI patients.
n (2 months data) Age (average) S.D.
All 484 63.8 12.8
Male 339(70%) 60.9 11.5
Female 145(30%) 70.7 13.2
Fig. 2 – Median of interval ‘‘symptoms-PCI’’ (total ischaemic
period) in patients treated with primary PCI. 
Fig. 1 – Ratio (%) of STEMI patients admitted within 12 h of
symptoms onset.
Fig. 3 – Change of reperfusion strategy within period 2007–
2011.
Fig. 4 – Hospital mortality in STEMI patients during 1998–
2011. (Data of 1998 comes from [3].)
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2011 an in-hospital mortality of 5.99%, a 30-day mortality of
10.7%, a one-year mortality of 14.6% and a two-year mortality
of 17.6% was recorded. The two-year survival of patients is
illustrated in Fig. 5. Women have a tendency towards worse
survival; however, the difference versus men did not reach aFig. 5 – Two-year survival of STEMI patients.
Fig. 6 – The comparison of men and women in two-year
survival of STEMI patients (p = 0.152).
Fig. 7 – The comparison of the two-year survival in patients
treated with primary PCI, thrombolysis and patients
without reperfusion treatment.
Fig. 8 – The comparison of the two-year survival between
patients treated with pharmacoinvasive strategy or
primary PCI.
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that patients with STEMI have a worse in-hospital prognosis
than patients with ACS without elevation of ST (NSTE-ACS);
however, in line with experiences from abroad it is shown that
surviving to one year is gradually balanced out and in the case
of NSTEMI the prognosis is in the end signiﬁcantly worse
(Table 4).
The two-year survival of patients treated with primary PCI
was signiﬁcantly better compared with patients without
primary reperfusion treatment (HR 0.4, 95% CI, p < 0.001) and
comparable with patients treated by thrombolysis (p = 0.66). A
total of 90.7% of patients after thrombolysis, however, subse-
quently underwent coronary angiography and as needed a
rescue or delayed PCI was performed. Fig. 7 illustrates the
prognosis according to the individual treatment strategies.
For the purpose of the analysis all cases of patients treated
with thrombolysis and subsequently examined by coronary
angiography (PCI) were considered as the pharmacoinvasive
strategy, and this is independent of whether the subsequent
coronary angiography was performed within 24 h or later. The
subgroup with pharmacoinvasive strategy tended to have the
best prognosis, however the beneﬁt versus the sub-group
treated with primary PCI did not achieve statistical signiﬁ-
cance (p = 0.164) (Fig. 8). The number of patients in pharma-
coinvasive group was small and study was not powered to
conﬁrm superiority in this ﬁnding.
We independently analysed the survival of the sub-group
of patients treated with primary PCI in relation to whether or
not they fulﬁlled the criterion interval of ECG-PCI ≤ 120 min.
Fig. 9 illustrates the trend in favour of patients satisfying this
criterion; the difference, however, did not achieve statisticalFig. 9 – The comparison of the two-year survival between
patients with primary PCI treated with ECG-PCI
interval > 120 min and ECG-PCI interval ≤ 120 min.
Table 4 – The comparison of mortality between various
type of ACS in Slovakia (NSTE-ACS data comes from [4].).
STEMI UA NSTEMI
Hospital mortality 5.99% NA 3.90%
30-days mortality 10.70% 0.96% 7.65%
6-months mortality 13.80% 3.65% 14.59%
12-months mortality 14.60% 6.54% 19.22%
Fig. 11 – The comparison of the two-year survival between
STEMI patients with diabetes and without diabetes.
Fig. 10 – The comparison of total ischaemic time
(symptoms-PPCI interval) between subgroup of two-year
survivors and subgroup of patients who have died.
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in the subsequent period, the median of the total ischaemic
time (the symptoms-PCI interval) was 300.5 min, while in
patients who survived to two years the median was 230.5 min.
This difference was statistically signiﬁcant (p = 0.043) and
conﬁrms the known fact that the battle over time in patients
with STEMI is relevant (Fig. 10). Signiﬁcantly worse two-year
survival was observed in diabetics (HR 1.63, 95% CI, p = 0.03)
(Fig. 11).
Discussion
In the last 15 years in Slovakia we have systematically
recorded a decrease in the mortality of STEMI. This can
be explained by better organisation of the transport,
improved availability of reperfusion therapy, mainly P-PCI,and introduction of modern pharmacotherapy. With the
assessments of these data, however, it is necessary to be
aware that the presented decrease of hospital mortality in
the SLOVAKS registry, or foreign registries, do not reﬂect the
real seriousness of the disease, since a notable portion of
patients with STEMI still die before ﬁrst contact with the
health care system. The most common cause of death in this
phase is malignant arrhythmia, mainly ventricular ﬁbrilla-
tion [5–7]. These patients logically do not ﬁgure into the
presented statistics. This ‘‘hidden’’ portion of the mortality
of STEMI has not changed very much. The overall mortality
of STEMI is therefore the result not only of the level of
immediate health care, but has a broader societal and social
background. An uneducated patient who does not know the
symptoms of a typical myocardial infarction can hesitate
with seeking help even for several hours, and his ‘‘total
ischaemic time’’ is dramatically extended, thus increasing
the risk of sudden death as a consequence of malignant
dysrhythmia, or a later death resulting from cardiogenic
shock due to serious dysfunction of the left ventricle. Since
2013 two additional cardiac centres have introduced contin-
uous 24-h operation of primary PCI in Slovakia. This fact
signiﬁcantly contributes to increasing the accessibility of
primary PCI, the shortening of overall ischaemic time and
thus improvement in patient prognosis nowadays.
Our analysis from 2011 documents very favourable in-
hospital mortality (5.99%) in the group of STEMI patients. A
comparison of the different types of ACS points to worse in-
hospital and 30-day mortality with STEMI (5.99% and 10.7%,
respectively) versus NSTEMI (3.9% and 7.65%, respectively)
[2,4]. In line with experiences abroad, after one year the
situation is reversed in Slovakia, since 12-month mortality was
14.6% with STEMI and 19.2% with NSTEMI. In literature in-
hospital mortality has been reported between 7 and 9.7% and
the 30-day mortality between 11.1 and 14% [8–10]. Both in-
hospital and 30-day mortality rates after STEMI have been
lower in clinical trials compared to registries and reports in
patients not in clinical trials. This has been explained by
enrollment of a lower risk population and better adherence to
proven therapies in the former.
More contemporary reports of patients not enrolled in trials
have documented a continued decline in mortality in STEMI
patients [11–13]. For example, outcomes were presented in a
2012 report of 6707 STEMI patients in four French nationwide
registries conducted ﬁve years apart (1995, 2000, 2005, and
2010) [14]. The following ﬁndings were noted:
 There were signiﬁcant decreases in crude 30-day mortality
(from 13.7 to 4.4%) and mortality standardised to 2010
population characteristics (from 11.3 to 4.4%). These
declines were seen irrespective of the type of reperfusion
(ﬁbrinolysis or PCI) and in patients who were not reperfused.
 Time from symptom onset to hospital admission decreased,
with a shorter time from onset to ﬁrst call, and broader use of
mobile intensive care units.
 During this time, the average age fell and the prevalence of
most risk factors increased.
 The use of reperfusion therapy increased from 50 to 75%,
driven mostly by an increase of the use of PCI, as did the use
of recommended preventative medical therapies.
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with ST-elevation myocardial infarction (STEMI), long-term
outcomes have been similar or worse with non-ST elevation
myocardial infarction (NSTEMI). The largest direct comparison
comes from the GUSTO-IIb trial performed in the early 1990s of
12,142 patients with STEMI, NSTEMI (using only CK-MB, not
troponins, for diagnosis), or unstable angina [15]. The
mortality rate at 30 days was lower with NSTEMI than STEMI
(3.8 versus 6.1%). In contrast, the mortality at one year was
similar (8.8 for NSTEMI versus 9.6% for STEMI). However,
outcomes from patients with NSTEMI managed more recently
were lower in the ISAR REACT 4 trial, in which mortality at one
year was about 4.4% [16].
Even though direct comparison of Slovak data with data
from abroad is problematic, it is obvious that upon comparing
the mortality, the data mainly from the in-hospital phase
holds up worthily. The mid-time survival of patients in
Slovakia tends to be markedly worse compared with data
from abroad. The explanations for this could be varied;
however, the possibility of worse secondary prevention is
suggestive and in patients with STEMI also the on-average
longer total ischaemic time results in worse functioning of
the left ventricle upon discharging. There is still remarkable
portion of patients treated with primary PCI with ECG-PPCI
interval above recommended 120 (resp. 90) minutes [17].
Results of STREAM [18] study and SLOVAKS registry as well
conﬁrm the idea of pharmacoinvasive strategy suitable for all
patients where recommended ECG-PPCI interval is unreach-
able. The National guidelines related to prehospital manage-
ment of STEMI patients were published recently and this
could help to improve total ischaemic time and optimise
antithrombotic medical treatment in Slovakia for the future
[19].
Limitations of the SLOVAKS registry follow from the
voluntary basis of reporting cases of ACS. It was not possible
to verify whether the linked workplaces reported all consecu-
tive cases of ACS in the subsequent period, and several
workplaces in Slovakia were not connected to the registry at
all. According to a qualiﬁed estimate, however, the SLOVAKS
registry in 2011 covered 80% of cases in-hospital STEMI, which
allows for the assumption of sufﬁcient representativeness of
the analysed sample. According to some works, the occurrence
of STEMI is higher in the winter months; therefore, the annual
calculation of our analysed two-month sample (August–
September) could be an underestimate.
Conclusion
In 2011 it was possible to record a continuation of the
favourable trend in the management of patients with STEMI
in Slovakia. Our experience showed that targeted initiatives
aimed at implementing ofﬁcial ESC guidelines into clinical
practice are meaningful and can signiﬁcantly change the
management of patients and improve clinical outcomes in a
relatively short period of time. The share of patients
admitted within 12 h grew signiﬁcantly; the share of patients
treated with primary PCI improved; the overall ischaemic
time was shortened; and the in-hospital mortality of STEMI
declined signiﬁcantly. A detailed analysis, however, pointsout several aspects in which there is potential for further
improvement of both the short-term and long-term progno-
sis of patients with STEMI. It will be possible to markedly
inﬂuence the total ischaemic time primarily through further
educational activities focused on typical symptoms of STEMI
and the need for timely calling of emergency medical help.
The greatest challenge for health care workers in the coming
years will be to ensure primary reperfusion treatment for
patients in the desired time intervals. In 2011 the importance
of pre-hospital ﬁbrinolysis provided to patients by EMS
personnel when it is not possible to reach primary PCI in the
required time window was still undervalued. Our analysis
conﬁrms the excellent prognosis of patients managed
through a pharmacoinvasive strategy. The mid-term surviv-
al of patients after ACS in Slovakia points to worse results in
comparison with results from abroad, which could be
associated with less consistent secondary prevention and
in patients with STEMI with an unfavourable length of total
ischaemic time.
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